|
Apr 1
|
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
|
|
Mar 19
|
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
|
|
Mar 18
|
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
|
|
Mar 12
|
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
|
|
Mar 6
|
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
|
|
Feb 7
|
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
|
|
Jan 9
|
Atossa Therapeutics Issues Letter to Shareholders
|
|
Dec 8
|
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
|
|
Dec 4
|
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
|
|
Nov 20
|
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
|
|
Nov 13
|
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 8
|
Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
|